Study Objective: The goal of this clinical research study is to learn how PLX8394 may affect cancer cells with mutations in the gene BRAF. PLX8394 is designed to block mutations in BRAF. These mutations can cause cancer and cancer cell growth. By blocking these mutations, the drug may kill the cancer cells with the mutation and/or stop the tumor from growing.
Sponsor: Plexxikon
Trial Contact Information: DivyaSakamuri; 1-713-745-3296; [email protected] or Filip Janku; 713-563-1930; [email protected]
Requested Patient Involvement: ECD patients greater than 18 years of age.
Known Centers Accepting ECD patients in the trial: MD Anderson, Houston, TX
ClinicalTrials.gov Identifier: NCT02428712